AC Immune S.A. (ACIU) Stock Price, Quote & News

Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, confor...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 21 345 91 21

Fax: 41 21 345 91 20

Website: www.acimmune.com

Address:

Building B, EPFL Innovation Park, Lausanne, Switzerland

doron2020 Aug. 26 at 3:41 AM

$ACIU quietly accumulating....see you all at 20$

0 · Reply

midas7576 Aug. 24 at 1:49 PM

$ACIU https://www.investing.com/news/analyst-ratings/ac-immune-stock-rating-reiterated-at-buy-by-hc-wainwright-93CH-4873324

0 · Reply

midas7576 Aug. 24 at 10:36 AM

$ACIU https://pharmaphorum.com/news/positive-ph1-results-ac-immunes-nlrp3-inflammasome-inhibitor

0 · Reply

Ou8mycookie Aug. 21 at 10:06 PM

$ACIU hoping they can partner ACI-19764 to fund ACI-7104. With good FDA input the phase 2 could be a pivotal trial for Parkinson’s. Don’t give up the golden goose with a partner on PD with such encouraging data.

0 · Reply

lucabrix Aug. 21 at 7:24 PM

$ACIU this is a 10$ stock that believes to be a 2$ stock!

0 · Reply

kshonstocks Aug. 21 at 2:33 PM

$ACIU hitting scans, approaching 200 dma

0 · Reply

prismmarketview Aug. 20 at 2:23 PM

$ACIU AC Immune Preliminary Phase 1/1b data for ACI-19764 (brain-penetrant NLRP3 inhibitor): safe/well tolerated up to 20mg/day, no serious adverse events, serum half-life >30 hours, clear CSF penetration, PK levels above IC90 at daily doses ≤10mg. Stock Titan Dose-dependent IL-1β inhibition also seen in blinded whole-blood analysis. Phase 1b cardiovascular-risk cohort dosing has now begun. Full H2 2026 readout is the next real catalyst — this is interim, not final data. https://prismmarketview.com/ac-immune-reports-early-phase-1-progress-for-brain-penetrant-nlrp3-inhibitor-aci-19764/

0 · Reply

Jparkhill Aug. 20 at 11:30 AM

$ACIU

0 · Reply

focafoca99 Aug. 20 at 11:19 AM

$ACIU revealed positive Phase 1 first-in-human data for its oral NLRP3 inhibitor ACI-19764.

0 · Reply

STACKD0E Aug. 20 at 11:12 AM

$ACIU $RADX $URGN $SHAZ 👁

0 · Reply

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

2026-08-11T11:41:42.000Z - 21 days ago

AC Immune receives fast track designation, clearance for ACI-7104 IND

Aug 5, 2026, 12:30 PM EDT - 26 days ago

AC Immune Earnings release: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 27 days ago

AC Immune First Half 2026 Financial and Corporate Update

Jul 7, 2026, 7:00 AM EDT - 2 months ago

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

2026-06-30T11:06:07.000Z - 2 months ago

AC Immune announces interim data from first three cohorts of ABATE trial

Jun 30, 2026, 7:00 AM EDT - 2 months ago

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease

Jun 11, 2026, 7:00 AM EDT - 2 months ago

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

Jun 5, 2026, 7:00 AM EDT - 3 months ago

AC Immune Slides: Investor presentation

2026-05-22T11:25:17.000Z - 3 months ago

AC Immune presents new Phase 1 data on uptake of ACI-19626

May 22, 2026, 7:00 AM EDT - 3 months ago

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

May 15, 2026, 7:01 AM EDT - 3 months ago

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care

May 12, 2026, 7:00 AM EDT - 4 months ago

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

2026-04-30T14:10:16.000Z - 4 months ago

AC Immune reports Q1 EPS (15c), consensus (14c)

Apr 30, 2026, 7:05 AM EDT - 4 months ago

AC Immune First Quarter 2026 Financial and Corporate Updates

Apr 30, 2026, 7:00 AM EDT - 4 months ago

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

Apr 30, 2026, 7:00 AM EDT - 4 months ago

AC Immune Earnings release: Q1 2026

Apr 8, 2026, 7:00 AM EDT - 5 months ago

AC Immune Slides: Investor presentation

2026-04-07T19:00:19.000Z - 5 months ago

Leerink calls AC Immune- Eli Lilly Tau amendment ‘great news’

LLY

2026-04-07T11:20:56.000Z - 5 months ago

AC Immune announces amendment to Eli Lilly license pact, to receive CHF 10M

LLY

Apr 7, 2026, 7:00 AM EDT - 5 months ago

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

2026-03-19T11:41:02.000Z - 5 months ago

AC Immune’s PET tracer shows efficacy detecting brain pathologies

2026-03-13T11:12:04.000Z - 6 months ago

AC Immune reports FY25 EPS (CHF 0.70) vs (CHF 0.51) last year

Mar 13, 2026, 7:00 AM EDT - 6 months ago

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

Mar 13, 2026, 7:00 AM EDT - 6 months ago

AC Immune Earnings release: Q4 2025

Mar 13, 2026, 7:00 AM EDT - 6 months ago

AC Immune Annual report: Q4 2025

Mar 13, 2026, 7:00 AM EDT - 6 months ago

AC Immune Slides: Investor presentation

2026-02-24T12:49:38.000Z - 6 months ago

AC Immune initiates Phase 1 trial of NLRP3 inhibitor

Dec 11, 2025, 9:00 AM EST - 9 months ago

AC Immune Transcript: Study Update

Dec 11, 2025, 9:00 AM EST - 9 months ago

AC Immune Press release: Study Update

Dec 11, 2025, 9:00 AM EST - 9 months ago

AC Immune Slides: Study Update

2025-12-11T12:30:27.000Z - 9 months ago

AC Immune’s Parkinson’s disease candidate shows positive Phase 2 results

Dec 11, 2025, 7:00 AM EST - 9 months ago

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease

Nov 18, 2025, 4:30 AM EST - 10 months ago

AC Immune Transcript: Jefferies London Healthcare Conference 2025

Nov 4, 2025, 1:00 PM EST - 10 months ago

AC Immune Earnings release: Q3 2025

2025-11-04T12:16:04.000Z - 10 months ago

AC Immune reports Q3 EPS (CHF 0.16) vs. CHF 0.05 last year

2025-11-04T12:15:45.000Z - 10 months ago

AC Immune sees cash runway to end of 3Q27

2025-11-04T12:15:40.000Z - 10 months ago

AC Immune reduced workforce by around 30% following strategic review

Nov 4, 2025, 7:00 AM EST - 10 months ago

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

2025-10-28T11:21:13.000Z - 11 months ago

AC Immune appoints Mummery as Chair of Clinical Advisory Board

2025-10-24T12:55:16.000Z - 11 months ago

AC Immune announces publication of preclinical data on ACI-19626

Oct 24, 2025, 8:50 AM EDT - 11 months ago

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine

2025-09-25T11:10:41.000Z - 1 year ago

AC Immune announces publication of results on ACI-35.030 in eBioMedicine

JNJ

2025-08-05T11:13:14.000Z - 1 year ago

AC Immune reports Q2 EPS (CHF 0.21) vs. (CHF 0.23) last year

2025-08-05T11:12:54.000Z - 1 year ago

AC Immune sees cash runway into 1Q27

Aug 5, 2025, 7:00 AM EDT - 1 year ago

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 5, 2025, 12:00 AM EDT - 1 year ago

AC Immune Earnings release: Q2 2025

2025-05-01T10:12:20.000Z - 1 year ago

AC Immune price target lowered to $12 from $16 at H.C. Wainwright

2025-04-30T11:08:49.000Z - 1 year ago

AC Immune reports Q1 EPS (19c) vs (18c) last year

Apr 30, 2025, 7:00 AM EDT - 1 year ago

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 29, 2025, 6:00 PM EDT - 1 year ago

AC Immune Earnings release: Q1 2025

Apr 29, 2025, 7:00 AM EDT - 1 year ago

AC Immune Slides: Investor Presentation

Apr 2, 2025, 6:00 AM EDT - 1 year ago

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

Mar 25, 2025, 7:00 AM EDT - 1 year ago

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

Mar 13, 2025, 7:00 AM EDT - 1 year ago

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

Mar 12, 2025, 7:00 PM EDT - 1 year ago

AC Immune Annual report: Q4 2024

Mar 12, 2025, 7:00 PM EDT - 1 year ago

AC Immune Earnings release: Q4 2024

Nov 20, 2024, 6:00 AM EST - 1 year ago

AC Immune Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

AC Immune Slides: Investor Presentation

Nov 4, 2024, 6:00 PM EST - 1 year ago

AC Immune Earnings release: Q3 2024

Aug 5, 2024, 6:00 PM EDT - 2 years ago

AC Immune Earnings release: Q2 2024

Jul 31, 2024, 8:30 AM EDT - 2 years ago

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

Jul 26, 2024, 8:00 AM EDT - 2 years ago

AC Immune Registration statement: Registration Filing

Jul 25, 2024, 7:00 AM EDT - 2 years ago

AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease

Jun 20, 2024, 7:00 AM EDT - 2 years ago

AC Immune Slides: FY 2024

Jun 5, 2024, 3:30 PM EDT - 2 years ago

AC Immune Transcript: Jefferies 2024 Global Healthcare Conference

May 29, 2024, 7:00 AM EDT - 2 years ago

AC Immune Slides: Investor Presentation

May 28, 2024, 7:00 AM EDT - 2 years ago

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

May 13, 2024, 8:47 AM EDT - 2 years ago

Alzheimer's vaccine licensing deal boosts AC Immune

May 13, 2024, 7:00 AM EDT - 2 years ago

AC Immune Earnings release: Q1 2024

May 13, 2024, 6:05 AM EDT - 2 years ago

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 13, 2024, 6:00 AM EDT - 2 years ago

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

TAK

Mar 14, 2024, 8:00 AM EDT - 2 years ago

AC Immune Annual report: Q4 2023

Mar 14, 2024, 8:00 AM EDT - 2 years ago

AC Immune Earnings release: Q4 2023

Mar 14, 2024, 8:00 AM EDT - 2 years ago

AC Immune Registration statement: Registration Filing

Mar 14, 2024, 7:00 AM EDT - 2 years ago

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Feb 22, 2024, 7:00 AM EST - 2 years ago

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

Jan 22, 2024, 7:00 AM EST - 2 years ago

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

Jan 3, 2024, 8:10 AM EST - 2 years ago

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

Dec 15, 2023, 7:56 AM EST - 2 years ago

AC Immune Announces Pricing of Underwritten Offering of Common Shares

Dec 15, 2023, 7:22 AM EST - 2 years ago

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

Dec 1, 2023, 7:00 AM EST - 2 years ago

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

Nov 7, 2023, 7:00 AM EST - 3 years ago

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

Nov 7, 2023, 7:00 AM EST - 3 years ago

AC Immune Slides: Investor Presentation

Nov 3, 2023, 8:00 AM EDT - 3 years ago

AC Immune Earnings release: Q3 2023

Nov 3, 2023, 7:00 AM EDT - 3 years ago

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Nov 2, 2023, 7:00 AM EDT - 3 years ago

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

Oct 27, 2023, 7:00 AM EDT - 3 years ago

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

Oct 17, 2023, 7:00 AM EDT - 3 years ago

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

Oct 5, 2023, 7:00 AM EDT - 3 years ago

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

Sep 5, 2023, 7:00 AM EDT - 3 years ago

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

Aug 4, 2023, 7:00 AM EDT - 3 years ago

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aug 4, 2023, 7:00 AM EDT - 3 years ago

AC Immune Earnings release: Q2 2023

Jul 28, 2023, 7:00 AM EDT - 3 years ago

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

Jul 26, 2023, 7:00 AM EDT - 3 years ago

AC Immune SA Appoints New Chief Medical Officer

Jul 3, 2023, 7:00 AM EDT - 3 years ago

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

Jun 27, 2023, 7:52 AM EDT - 3 years ago

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

Jun 27, 2023, 7:00 AM EDT - 3 years ago

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease

Jun 23, 2023, 4:30 PM EDT - 3 years ago

AC Immune Holds Annual General Meeting of Shareholders

Apr 28, 2023, 7:00 AM EDT - 3 years ago

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Apr 28, 2023, 7:00 AM EDT - 3 years ago

AC Immune Earnings release: Q1 2023

Apr 5, 2023, 7:00 AM EDT - 3 years ago

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease

Mar 20, 2023, 8:00 AM EDT - 3 years ago

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

doron2020 Aug. 26 at 3:41 AM

$ACIU quietly accumulating....see you all at 20$

0 · Reply

midas7576 Aug. 24 at 1:49 PM

$ACIU https://www.investing.com/news/analyst-ratings/ac-immune-stock-rating-reiterated-at-buy-by-hc-wainwright-93CH-4873324

0 · Reply

midas7576 Aug. 24 at 10:36 AM

$ACIU https://pharmaphorum.com/news/positive-ph1-results-ac-immunes-nlrp3-inflammasome-inhibitor

0 · Reply

Ou8mycookie Aug. 21 at 10:06 PM

0 · Reply

lucabrix Aug. 21 at 7:24 PM

$ACIU this is a 10$ stock that believes to be a 2$ stock!

0 · Reply

kshonstocks Aug. 21 at 2:33 PM

$ACIU hitting scans, approaching 200 dma

0 · Reply

prismmarketview Aug. 20 at 2:23 PM

0 · Reply

Jparkhill Aug. 20 at 11:30 AM

$ACIU

0 · Reply

focafoca99 Aug. 20 at 11:19 AM

$ACIU revealed positive Phase 1 first-in-human data for its oral NLRP3 inhibitor ACI-19764.

0 · Reply

STACKD0E Aug. 20 at 11:12 AM

$ACIU $RADX $URGN $SHAZ 👁

0 · Reply

midas7576 Aug. 20 at 11:11 AM

$ACIU https://finance.yahoo.com/healthcare/articles/ac-immune-announces-positive-preliminary-110000047.html

0 · Reply

midas7576 Aug. 20 at 11:03 AM

$ACIU https://uk.advfn.com/stock-market/NASDAQ/ACIU/share-news/Form-6-K-Report-of-foreign-issuer-Rules-13a-16/99162717

0 · Reply

AIIAAIIA_88 Aug. 18 at 11:20 PM

$ACIU The end of 2026 PT = $20. Yes, that is my story and I am sticking with it. JMO

1 · Reply

CTL1985 Aug. 15 at 10:37 PM

$ACIU 👀👀🤷‍♂️👀👀 NFA🧐😁

0 · Reply

AIIAAIIA_88 Aug. 13 at 7:15 PM

$ACIU $PRTA $AVXL Will this one be the winner on the AD/PD field? This field has been a graveyard for so many drug candidates…. I have 3-5-7 year horizon with my position with this one just established.

0 · Reply

CTL1985 Aug. 13 at 10:58 AM

$GORO 👀👀 $CTM 👀👀 $ONDS 👀👀 $ACIU 👀👀 $NUVB 👀👀

0 · Reply

Trip1801 Aug. 11 at 7:15 PM

$ACIU Are there any milestone payments that can be achieved with the other programs next half year? Cash runway is a serious threat. Or do you think they try to find a partner for this program as well? I would prefer developing that one alone, but cash is a problem. Maybe sell one of the other programs? Developing medicine becomes more and more expensive.

0 · Reply

prismmarketview Aug. 11 at 6:23 PM

$ACIU’s ACI-7104 has gained FDA Fast Track status in early Parkinson’s disease, supporting more frequent FDA interactions and potentially expedited review pathways. In Phase 2 interim data, the therapy was well tolerated and achieved a 100% immune-response rate. https://prismmarketview.com/ac-immune-speeds-toward-a-potential-parkinsons-breakthrough-with-fda-fast-track-status/

0 · Reply

ajmrtxl Aug. 11 at 4:19 PM

$ACIU 's latest data on SqueezeFinder

1 · Reply

StocktwitsNews Aug. 11 at 4:18 PM

ACIU Stock Heads For Best Day In Over 10 Months On FDA Fast Track Nod For Parkinson’s Disease Therapy – Retail Sees ‘Breakout Soon’ $ACIU https://stocktwits.com/news/equity/markets/why-is-aciu-stock-soaring-today/cZoNT0FRJXR

0 · Reply

SHVR89 Aug. 11 at 4:08 PM

$ACIU October - November

0 · Reply

Merlintrader Aug. 11 at 4:03 PM

AC Immune ($ACIU) Stock Hub 2026: Fast Track For ACI-7104, The VacSYn Week-100 Readout And A Runway Into Q4 2027 https://www.merlintrader.com/ac-immune-aciu-stock-hub-2026/

0 · Reply

Market Cap	269.70M
Revenue (ttm)	4.31M
Net Income (ttm)	-85.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,972.85%
Debt to Equity Ratio	0.00

Volume	132,900
Avg Vol	238,990
Day's Range	N/A - N/A
Shares Out	101.77M
Stochastic %K	36%
Beta	1.59
Analysts	Strong Sell
Price Target	$9.00